Toward Developing Alternative Opioid Antagonists for Treating Community Overdose: A Model‐Based Evaluation of Important Pharmacological Attributes
Clinical Pharmacology & Therapeutics · 2025-03 · 117 (3) · 836-845
DOI: 10.1002/cpt.3527 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 28.01.2025. Verfasst von Anik Chaturbedi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, F…. Hauptthemen laut MEDLINE: Narcotic Antagonists, Naloxone, Analgesics, Opioid, Naltrexone. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural FDA HHS.
Abstract (Originalsprache)
In response to increased illicit use of synthetic opioids, various μ‐receptor antagonist formulations, with varied pharmacological characteristics, have been and are being developed. To understand how pharmacologic characteristics such as absorption rate and clearance rate affect reversal in treating community opioid overdose, we used our previously published translational opioid model. We adapted this model with in vitro receptor binding data and clinical pharmacokinetic data of three intranasal nalmefene formulations along with an intranasal naloxone formulation to study the reversal of fentanyl and carfentanil‐induced respiratory depression in chronic opioid users. Nalmefene has a longer plasma half‐life and slower unbinding from the μ‐receptor compared to naloxone. For a more rapid reversal of acute overdose‐induced respiratory depression, a fast‐absorbing antagonist formulation may be of greater utility than a slow‐absorbing one containing the same dosage of the antagonist. For preventing renarcotization caused by a long opioid exposure, a slow‐clearing antagonist with slow unbinding from the receptor may be of value. While a more potent antagonist with a longer half‐life may have the potential to facilitate recovery from respiratory depression for overdose with synthetic opioids, such interventions may also lead to longer and more pronounced withdrawal. This emphasizes the need for a nuanced consideration of several facets while choosing a μ‐receptor antagonist, dose, and formulation to treat community opioid overdose cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food & Drug Administration, Silver Spring, Maryland, USA.
- Division of Neuropsychiatric Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food & Drug Administration, Silver Spring, Maryland, USA.
ORCID-Profile: Anik Chaturbedi, Bradlee Thrasher, Joel Zirkle, Srikanth C Nallani, Zhihua Li
Förderung
- Intramural FDA HHS
Zitieren
APA
Chaturbedi, A., Mann, J., Chakravartula, S., Thrasher, B., Arabidarrehdor, G., Zirkle, J., Meshkin, H., Nallani, S. C., Florian, J., & Li, Z. (2025). Toward Developing Alternative Opioid Antagonists for Treating Community Overdose: A Model‐Based Evaluation of Important Pharmacological Attributes. Clinical Pharmacology & Therapeutics, 117(3), 836-845. https://doi.org/10.1002/cpt.3527
Vancouver
Chaturbedi A, Mann J, Chakravartula S, Thrasher B, Arabidarrehdor G, Zirkle J, et al. Toward Developing Alternative Opioid Antagonists for Treating Community Overdose: A Model‐Based Evaluation of Important Pharmacological Attributes. Clinical Pharmacology & Therapeutics. 2025;117(3):836-845. doi:10.1002/cpt.3527
BibTeX
@article{Chaturbedi2025,
author = {Chaturbedi, Anik and Mann, John and Chakravartula, Shilpa and Thrasher, Bradlee and Arabidarrehdor, Ghazal and Zirkle, Joel and Meshkin, Hamed and Nallani, Srikanth C and Florian, Jeffry and Li, Zhihua},
title = {Toward Developing Alternative Opioid Antagonists for Treating Community Overdose: A Model‐Based Evaluation of Important Pharmacological Attributes},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {117},
number = {3},
pages = {836--845},
doi = {10.1002/cpt.3527}
}
EUVIMED